Bivatuzumab
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].
Product Specifications
CAS Number
[214559-60-1]
Product Name Alternative
BIWA 4; Anti-CD44 Recombinant Antibody
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bivatuzumab.html
Purity
99.82
Solubility
10 mM in DMSO
Smiles
[Bivatuzumab]
Molecular Weight
(143.22 kDa)
References & Citations
[1]Leuci V, et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7 (5) :e1423167.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1103268-01 0.02 mg (E-Coli)
Recombinant Campylobacter lari DNA-directed RNA polymerase subunit omega (rpoZ)
Ask
View Details MBS1103268-02 0.1 mg (E-Coli)
Recombinant Campylobacter lari DNA-directed RNA polymerase subunit omega (rpoZ)
Ask
View Details 
MBS1103268-03 0.02 mg (Yeast)
Recombinant Campylobacter lari DNA-directed RNA polymerase subunit omega (rpoZ)
Ask
View Details MBS1103268-04 0.1 mg (Yeast)
Recombinant Campylobacter lari DNA-directed RNA polymerase subunit omega (rpoZ)
Ask
View Details